Abstract 2843: Development of a binary diagnostic immunofluorescence assay by AQUA® technology for accurate detection of HER-2 levels in breast cancer specimens
Lakshmi Chandrasekaran(St George's, University of London), Nagesh Rao(APLA Health), Sue Beruti(Novartis (United States)), Mike Nerenberg(Novartis (United States)), David L. Rimm(Yale University), Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Bruce A. Robbins(Scripps Health), Jelveh Lameh(Lineage Cell Therapeutics (United States)), Armin Graber(Novartis (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States))
Cited by 0
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
|JAMA Oncology|2015|834
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753